A Clinical Study of T3011 in Subjects With Advanced Melanoma

Inclusion Criteria:

1. Subjects with advanced melanoma;

2. At least one measurable lesion;

3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;

4. Expected survival > 12 weeks;

5. Laboratory inspection meets the requirements;

6. For women of childbearing potential, the serum pregnancy test results must benegative within 7 days prior to the first dose，and effective contraceptive measuresmust be taken from signing the informed consent form (ICF) until at least 6 monthsafter the last dose;

7. Male subjects of childbearing potential agree to use effective contraception fromsigning the ICF until at least 6 months after the last dose; In addition, malesubjects must agree not to donate sperm during this period;

8. Understand and voluntarily sign the ICF，willing and able to comply with allexperimental requirements.

Exclusion Criteria:

1. Subjects who have received other antitumor therapy within the prescribed time priorto the first dose;

2. Subjects with a history of other malignancies within the prescribed time prior tothe start of study treatment.

3. At screening, subjects with a history or evidence of high risk cardiovasculardisease;

4. Subjects with persistent or active infection requiring intravenous anti-infectivetherapy;

5. Subjects with autoimmune diseases or a history of autoimmune diseases;

6. Subjects with known psychiatric disorders that may affect trial compliance;

7. Subjects who have pleural effusion, pericardial effusion, or ascites before startingtreatment and require puncture drainage, or who had received puncture drainagewithin the specified time before starting the study treatment;

8. Subjects requiring systemic treatment with anti-HSV drugs during the study period;

9. Subjects who have received live or attenuated vaccines within the prescribed timeprior to the first dose, or who plan to receive such vaccines during the studyperiod; Subjects who have received any tumor vaccine in the past;

10. Subjects who had undergone major surgery within the prescribed time before the firstdose，and had not recovered from surgery-related adverse reactions or were still inthe postoperative recovery period，or who plan to undergo major surgery during thestudy period;

11. Subjects with a history of drug use，drug abuse or alcohol abuse within the yearprior to signing the ICF;

12. Female subjects who are pregnant or breastfeeding, or planning to conceive or havechildren during the study period;

13. The investigator considers it inappropriate to participate in this study.